Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enzymatic Therapy

This article was originally published in The Tan Sheet

Executive Summary

Three products added to firm's heart health line, including Vitaline CoQ10, Vitaline L-Carnitine and Eskimo 3, a fish oil supplement. Line also includes Heart Health Formula, Formula to Retain Healthy Cholesterol Levels and Allicin 5000, a once-a-day garlic supplement. Updated packaging for the line features guidelines to help consumers determine their own dosage level. A print ad campaign for Vitaline CoQ10 is scheduled to begin in May and will run through year end. A 30-count of 100 mg Vitaline CoQ10 chews in chocolate and maple flavors will retail for $34.50. A 60-count of Vitaline L-Carnitine softgels will sell for $36.95 and 105 Eskimo-3 softgels will cost $19.95

You may also be interested in...



High-Dose CoQ10 Research Urged In UCSD Early Parkinson’s Study

Early-stage Parkinson's disease patients given 1,200 mg/day coenzyme Q10 experienced slower disease progression than those receiving 300 mg/d, 600 mg/d or placebo, a recent Phase II study found

High-Dose CoQ10 Research Urged In UCSD Early Parkinson’s Study

Early-stage Parkinson's disease patients given 1,200 mg/day coenzyme Q10 experienced slower disease progression than those receiving 300 mg/d, 600 mg/d or placebo, a recent Phase II study found

High-Dose CoQ10 Research Urged In UCSD Early Parkinson’s Study

Early-stage Parkinson's disease patients given 1,200 mg/day coenzyme Q10 experienced slower disease progression than those receiving 300 mg/d, 600 mg/d or placebo, a recent Phase II study found

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel